Sun Pharma FY26 net profit rises 5% to ₹114,794 million
Sun Pharmaceutical Industries reported a 5% rise in FY26 net profit to ₹114,794 million, supported by an 11.9% increase in revenue to ₹582,201 million. The Global Innovative Medicine business grew 16.8% for the year, while India formulation sales increased by 14%. The U.S. business saw a marginal decline for the full year. The company has recommended a total dividend of ₹16.00 per share and provided guidance for high single-digit revenue growth in FY27.
*this image is generated using AI for illustrative purposes only.
Sun Pharmaceutical Industries reported its audited financial results for the quarter and year ended March 31, 2026. The company recorded consolidated revenue of ₹582,201 million for the full year, an increase of 11.9% compared to ₹520,413 million in the previous year. For the fourth quarter, revenue stood at ₹146,118 million, reflecting a year-on-year increase from ₹129,588 million. The board recommended a final dividend of ₹5.00 per share, taking the total dividend for FY26 to ₹16.00 per share.
Financial Performance at a Glance
The key financial metrics for the year and quarter are summarised below:
| Metric: | FY26 Current | FY25 Previous | Q4 Current | Q4 Previous |
|---|---|---|---|---|
| Revenue: | ₹582,201 million | ₹520,413 million | ₹146,118 million | ₹129,588 million |
| Net Profit: | ₹114,794 million | ₹109,290 million | ₹27,140 million | ₹21,499 million |
| EBITDA: | ₹177,314 million | ₹152,717 million | ₹39,542 million | ₹37,161 million |
| EBITDA Margin: | 30.3% | 29.0% | 27.1% | 28.7% |
Profitability and Operational Highlights
The company's consolidated net profit for FY26 rose to ₹114,794 million, a 5.0% increase from the prior year. Q4 net profit grew 26.2% year-on-year to ₹27,140 million. EBITDA for the full year increased by 16.1% to ₹177,314 million, with the margin expanding to 30.3%. However, the Q4 EBITDA margin narrowed to 27.1% from 28.7% in the year-ago period. The company reported a net cash position of $3.2 billion at the consolidated level.
Segment Performance
Global Innovative Medicine sales for the full year FY26 were $1,420 million, a growth of 16.8%. In Q4 FY26, these sales were up 20.1% to $354 million. India formulation sales for the full year were ₹192,904 million, recording a growth of 14%, while Q4 sales reached ₹48,359 million. The U.S. business reported sales of $459 million for the quarter, declining by 1.1%, with full year sales at $1.9 billion. Formulation revenues in Emerging Markets were $306 million in Q4, up 17.4%, and $1.265 billion for the full year, up 13.6%.
Guidance and Outlook
The company expects high single-digit consolidated top line growth for FY27. R&D spend for FY27 is expected to be 6% to 7% of sales. The effective tax rate for the coming year is anticipated to be in the range of 25%. The company also provided an update on the acquisition of Organon & Company, expecting completion in Q4 FY27.
Historical Stock Returns for Sun Pharmaceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.75% | +1.55% | -3.47% | +0.03% | +6.93% | +165.33% |
What specific factors are expected to drive the high single-digit revenue growth guidance for FY27?
How will the acquisition of Organon & Company impact Sun Pharma's revenue diversification and market position?
What strategies will Sun Pharma employ to address the declining sales in the U.S. market?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
